405 related articles for article (PubMed ID: 30054667)
1. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.
Garg AD; Vandenberk L; Koks C; Verschuere T; Boon L; Van Gool SW; Agostinis P
Sci Transl Med; 2016 Mar; 8(328):328ra27. PubMed ID: 26936504
[TBL] [Abstract][Full Text] [Related]
3. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.
Maes W; Rosas GG; Verbinnen B; Boon L; De Vleeschouwer S; Ceuppens JL; Van Gool SW
Neuro Oncol; 2009 Oct; 11(5):529-42. PubMed ID: 19336528
[TBL] [Abstract][Full Text] [Related]
4. Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma.
Dey M; Chang AL; Miska J; Wainwright DA; Ahmed AU; Balyasnikova IV; Pytel P; Han Y; Tobias A; Zhang L; Qiao J; Lesniak MS
J Immunol; 2015 Jul; 195(1):367-76. PubMed ID: 26026061
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis.
Cao JX; Zhang XY; Liu JL; Li D; Li JL; Liu YS; Wang M; Xu BL; Wang HB; Wang ZX
PLoS One; 2014; 9(9):e107173. PubMed ID: 25215607
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.
Hunn MK; Farrand KJ; Broadley KW; Weinkove R; Ferguson P; Miller RJ; Field CS; Petersen T; McConnell MJ; Hermans IF
Clin Cancer Res; 2012 Dec; 18(23):6446-59. PubMed ID: 23147997
[TBL] [Abstract][Full Text] [Related]
7. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.
Prins RM; Wang X; Soto H; Young E; Lisiero DN; Fong B; Everson R; Yong WH; Lai A; Li G; Cloughesy TF; Liau LM
J Immunother; 2013 Feb; 36(2):152-7. PubMed ID: 23377664
[TBL] [Abstract][Full Text] [Related]
8. Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination.
Ardon H; Verbinnen B; Maes W; Beez T; Van Gool S; De Vleeschouwer S
J Immunol Methods; 2010 Jan; 352(1-2):169-73. PubMed ID: 19874827
[TBL] [Abstract][Full Text] [Related]
9. CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.
Murphy KA; Erickson JR; Johnson CS; Seiler CE; Bedi J; Hu P; Pluhar GE; Epstein AL; Ohlfest JR
J Immunol; 2014 Jan; 192(1):224-33. PubMed ID: 24293627
[TBL] [Abstract][Full Text] [Related]
10. Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
Sanchez-Perez LA; Choi BD; Archer GE; Cui X; Flores C; Johnson LA; Schmittling RJ; Snyder D; Herndon JE; Bigner DD; Mitchell DA; Sampson JH
PLoS One; 2013; 8(3):e59082. PubMed ID: 23527092
[TBL] [Abstract][Full Text] [Related]
11. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM
Nat Commun; 2024 May; 15(1):3882. PubMed ID: 38719809
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
[TBL] [Abstract][Full Text] [Related]
13. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Banissi C; Ghiringhelli F; Chen L; Carpentier AF
Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.
Chang CN; Huang YC; Yang DM; Kikuta K; Wei KJ; Kubota T; Yang WK
J Clin Neurosci; 2011 Aug; 18(8):1048-54. PubMed ID: 21715171
[TBL] [Abstract][Full Text] [Related]
15. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
[TBL] [Abstract][Full Text] [Related]
16. An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma.
Zhu S; Lv X; Zhang X; Li T; Zang G; Yang N; Wang X; Wu J; Chen W; Liu YJ; Chen J
Int J Cancer; 2019 Jun; 144(11):2867-2879. PubMed ID: 30565657
[TBL] [Abstract][Full Text] [Related]
17. Intrinsically de-sialylated CD103(+) CD8 T cells mediate beneficial anti-glioma immune responses.
Jouanneau E; Black KL; Veiga L; Cordner R; Goverdhana S; Zhai Y; Zhang XX; Panwar A; Mardiros A; Wang H; Gragg A; Zandian M; Irvin DK; Wheeler CJ
Cancer Immunol Immunother; 2014 Sep; 63(9):911-24. PubMed ID: 24893855
[TBL] [Abstract][Full Text] [Related]
18. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.
El Andaloussi A; Han Y; Lesniak MS
J Neurosurg; 2006 Sep; 105(3):430-7. PubMed ID: 16961139
[TBL] [Abstract][Full Text] [Related]
19. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.
Lasky JL; Panosyan EH; Plant A; Davidson T; Yong WH; Prins RM; Liau LM; Moore TB
Anticancer Res; 2013 May; 33(5):2047-56. PubMed ID: 23645755
[TBL] [Abstract][Full Text] [Related]
20. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.
Zhu X; Lu C; Xiao B; Qiao J; Sun Y
J Neurooncol; 2005 Aug; 74(1):9-17. PubMed ID: 16078102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
